Trials / Recruiting
RecruitingNCT06461182
Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
Ga-68-CXCR4 PET/CT in Detecting, Evaluating Response to Treatment, and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Koo Foundation Sun Yat-Sen Cancer Center · Academic / Other
- Sex
- All
- Age
- 20 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ga-68-CXCR4 | Ga-68-CXCR4 for PET/CT procedure in Indolent B-cell Lymphoma |
Timeline
- Start date
- 2024-04-29
- Primary completion
- 2026-04-01
- Completion
- 2027-04-01
- First posted
- 2024-06-14
- Last updated
- 2024-06-14
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT06461182. Inclusion in this directory is not an endorsement.